For a succinct analysis of 1H 2024 venture investment and exit activity in life sciences and health care, take a look at HSBC’s Venture Healthcare Report, Shake it off: HSBC Innovation Banking Analysis, 1H 2024. Lead author Jonathan Norris and his team analyze early stage, venture deals, private M&A and IPO activity in Healthtech, Med Device, Biopharma, and Dx/Tools, in both the United States and Europe. The Report also provides a deep dive into growth and investment in computational biology.
Several key findings of the Report are:
- 1H 2024 investments in Healthtech reversed the 2023 decline with deal activity rising each quarter. The sector also experienced a surge in earlier-stage deals.
- Med device investments are reported to remain stable in large part to an increase in first-financing deals and dollars in 2Q 2024. An increase in early-stage investments in deals requiring robust clinical trials, particularly in neurology.
- For Biopharma, the Report highlights exists and a strong M&A market for growth in the sector. Investment in Biopharma reportedly increased by 35%, and there were 51 private deals exceeding $100 million.
- Dx/Tools sector experienced a decline in first-financing deals. A resurgence of growth investors for companies reaching commercialization provided a bright spot for this sector. Early-stage valuations are reported to remain strong but companies with “lofty” valuations from 2020-2021 experienced down or flat rounds.
The Report summarizes that 1H 2024 experienced increased investment across every analyzed sector with numerous investor-led financings. IPO interest increased in Biopharma as well as high deal-value private M&A.
Author(s)
Related Insights
November 19, 2026
Tariff & International Trade Resource
What Every Multinational Should Know About … Rising Enforcement Risks Linked to Criminal Organizations and Cartels in Latin America
Recent developments in the United States and across Latin America point to a steadily intensifying enforcement environment targeting criminal organizations and cartels active in the region.
November 19, 2026
Manufacturing Industry Advisor
From EVs to Energy Storage: What Automotive Companies Should Know Before Pivoting to Data Centers and the Grid
The automotive industry prepared for an electric vehicle (EV) future that has not yet come to fruition. In 2024, forecasters projected that EVs would account for 46% to 50% of U.S. passenger vehicle sales by 2030; more recent projections put that figure at just 20% to 24%.[1] At the same time, demand for energy storage systems (ESS) is surging, driven by utility and grid needs and, increasingly, by the power demands of data centers and the artificial intelligence (AI) economy. A growing number of EV manufacturers and suppliers are now redirecting underused battery capacity toward stationary energy storage. The opportunity is real, but so are the risks: storage is a different business, with different customers, contract structures, and liability exposures. This article outlines the key incentive, contract, warranty, and product liability issues that in-house legal and business leaders should address before making the pivot from EV to ESS.
November 18, 2026
Foley Career Perspectives
Know Your Normal: Foley Best Self Highlights Cancer Awareness and Health Advocacy
Foley & Lardner endeavors to create a culture that encourages every member of the firm to be their “Best Self.” Providing an environment where people can bring their Best Self each day enhances our ability to attract and retain top talent and provide the very best client service.